Health Care Systems
Health care systems organise the finance and delivery of health care. They vary by country, reflecting specific history, culture, and economics. To maximise coverage and efficiency they must evolve with changing demographics, needs, and technologies.
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to impose a substantial global burden, with millions of cases and high mortality each year. Patients with bloodstream…
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
31 March 2026
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible for substantial health and economic burden to health systems and wider society.
Europe’s pharmaceutical policy choices – And what the United States stands to learn
18 March 2026
A recent policy discussion on Capitol Hill hosted by We Work For Health examined the lessons the United States might draw from Europe’s experience with pharmaceutical pricing and innovation. As a participant, my key takeaways focused on understanding the trade-offs underpinning EU and UK drug pricing policy and the broader impact on innovation for both sides of the Atlantic.
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special thanks to Salah Ghabri for his valuable support to write this note.
NICE’s new cost-effectiveness threshold: Significance, consequences, and unanswered questions
25 February 2026
NICE’s cost-effectiveness threshold will rise in April 2026, for the first time in 20 years. This raises important questions to consider as we approach the change and in the years that follow.
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
The value of cell and gene therapies to the UK economy
20 October 2025
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development.
Turning around the NHS: Reflections on the 2025 OHE Annual Lecture
14 October 2025
In this year’s Annual Lecture, Prof Anita Charlesworth takes a closer look at the NHS 10 Year Health Plan, concluding that all is not lost for the NHS, but questions of coherence, capacity, and capability remain.
OHE’s submission to a parliamentary inquiry on UK drug shortages
6 October 2025
The following is an extract from OHE’s written submission to parliament focused on diversifying suppliers and recognising the value of treatment alternatives to mitigate this issue.